Catalyst Pharma

@CatalystPharma

Bringing patients quality, safe and effective drugs for orphan diseases. See our social media guidelines:

Coral Gables, FL
Vrijeme pridruživanja: listopad 2013.

Tweetovi

Blokirali ste korisnika/cu @CatalystPharma

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @CatalystPharma

  1. 4. velj

    We are proud to welcome David Ailinger as Vice President of Business Development to our team. Learn more >>>

    Poništi
  2. 29. svi 2018.

    Catalyst Pharmaceuticals announces FDA acceptance of NDA and Priority Review Status for Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS):

    Poništi
  3. 20. tra 2018.

    Catalyst Pharmaceuticals announces first patient enrolled in Phase 3 trial of Firdapse in MuSK positive myasthenia gravis (MuSK-MG)

    Poništi
  4. 29. ožu 2018.

    Catalyst Pharmaceuticals announces NDA submission for Firdapse to the U.S. Food and Drug Administration for the treatment of Lambert-Eaton myasthenic syndrome (LEMS):

    Poništi
  5. 14. ožu 2018.

    Catalyst reports fourth quarter financial results:

    Poništi
  6. 12. ožu 2018.

    Catalyst to report fourth quarter financial results and host conference call:

    Poništi
  7. 28. velj 2018.

    Catalyst Pharmaceuticals is pleased to announce its support for 2018:

    Poništi
  8. 12. velj 2018.

    Catalyst Pharmaceuticals announces plans to resubmit New Drug Application:

    Poništi
  9. 22. stu 2017.

    Catalyst begins trial in Italy for patients with rare disease spinal muscular atrophy (SMA) Type 3. The trial will evaluate if amifampridine treatment can provide symptomatic relief by addressing impaired transmission at the neuromuscular junction:

    Poništi
  10. 14. stu 2017.

    Myasthenia gravis can affect people of any age, but it's more common in women younger than 40 and in men older than 60.

    Poništi
  11. 9. stu 2017.

    Catalyst reports third quarter financial results:

    Poništi
  12. 8. stu 2017.

    Catalyst to report third quarter financial results and host conference call:

    Poništi
  13. 18. lis 2017.

    Catalyst is dedicated to delivering the first approved therapy for Lambert-Eaton myasthenic syndrome (LEMS):

    Poništi
  14. 11. lis 2017.

    Lambert-Eaton myasthenic syndrome (LEMS) is a rare and debilitating disease that leads to muscle weakness and affects movement

    Poništi
  15. 3. lis 2017.

    Lambert-Eaton myasthenic syndrome (LEMS) is a progressive and life-threatening disorder. Learn more:

    Poništi
  16. 19. ruj 2017.

    Children and families living with unfortunately have one thing in common: delayed diagnosis;

    Poništi
  17. 14. ruj 2017.

    Proud to participate in RARE Patient Advocacy Summit in support of patients, families & fellow advocates

    Poništi
  18. 6. ruj 2017.

    Lambert-Eaton Myasthenic Syndrome is a rare autoimmune disease that can be severely disabling. Learn more:

    Poništi
  19. 24. kol 2017.

    MuSK-MG is characterized by a high incidence of respiratory crises & resistance to treatment

    Poništi
  20. 21. kol 2017.

    MuSK-MG is an ultra-rare and debilitating neuromuscular disease. . Learn more:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·